Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.

ABSTRACT:

Importance

Approval by the US Food and Drug Administration of immune checkpoint inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status has generated controversy. Exploratory analyses from individual trials indicate a lack of meaningful benefit from ICI in patients with absent or low PD-L1 expression; however, analysis of a single variable while ignoring others may not consider the instability inherent in exploratory analyses.

Objective

To systematically examine the predictive value of tissue-based PD-L1 status compared with that of other variables for ICI benefit in aGEC to assess its stability.

Data sources

MEDLINE, Embase, Scopus, Web of Science, Cochrane Central Register (2000-2022).

Study selection, data extraction, and synthe

SUBMITTER: Yoon HH 

PROVIDER: S-EPMC9412834 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature